Search Within

Alan Loh Ho

  1. "Endocrinology"
Formats
  1. Journal Article (18)
  2. Meeting Abstract (16)
  3. Editorial (1)
  4. Guidelines (1)
Groups
  1. Department of Medicine (36)
  2. Division of Subspecialty Medicine (36)
  3. Endocrinology (36)
  4. Head and Neck Service (36)
  5. Solid Tumor Oncology Division (36)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (30)

More Groups

People
  1. James Fagin (30)
  2. Eric Sherman (23)
  3. Ronald Ghossein (22)
  4. Robert Tuttle (20)
  5. David Pfister (17)
  6. Ravinder Grewal (15)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. European Journal of Nuclear Medicine and Molecular Imaging (3)
  3. Thyroid (3)
  4. Cancer (2)
  5. Cancer Research (2)
  6. Journal of Nuclear Medicine (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. American Association for Cancer Research (5)
  3. Springer (4)
  4. Mary Ann Liebert, Inc (3)
  5. Oxford University Press (2)
  6. Society of Nuclear Medicine (2)

More Publishers

Results (36)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy
    Journal Article

    Boucai, L.; Saqcena, M.; Kuo, F.; Grewal, R. K.; Socci, N.; Knauf, J. A.; Krishnamoorthy, G. P.; Ryder, M.; Ho, A. L.; Ghossein, R. A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • PTEN loss-of-function mutations prevalent in HRAS-mutant cancers results in resistance to targeted therapy
    Meeting Abstract

    Nigam, A.; Chatila, W. K.; Krishnamoorthy, G. P.; Ho, A. L.; Fagin, J. A.; Schultz, N. D.; Untch, B. R.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: A phase III, randomized, placebo-controlled trial (ASTRA)
    Journal Article

    Ho, A. L.; Dedecjus, M.; Wirth, L. J.; Tuttle, R. M.; Inabnet, W. B. 3rd; Tennvall, J.; Vaisman, F.; Bastholt, L.; Gianoukakis, A. G.; Rodien, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer
    Journal Article

    Lee, N. Y.; Riaz, N.; Wu, V.; Brinkman, T.; Tsai, C. J.; Zhi, W.; Fetten, J.; Ho, A.; Wong, R. J.; Ghossein, R.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
    Guidelines

    Shonka, D. C. Jr; Ho, A.; Chintakuntlawar, A. V.; Geiger, J. L.; Park, J. C.; Seetharamu, N.; Jasim, S.; Abdelhamid Ahmed, A. H.; Bible, K. C.; Brose, M. S.; more...
    Head & Neck (2022)

    Fulltext@MSK | Save
  • Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ERBB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial
    Journal Article

    Tchekmedyian, V.; Dunn, L.; Sherman, E.; Baxi, S. S.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy
    Journal Article

    Lee, M.; Untch, B. R.; Xu, B.; Ghossein, R.; Han, C.; Kuo, F.; Valero, C.; Nadeem, Z.; Patel, N.; Makarov, V.; more...
    Molecular Cancer Research (2022)

    Fulltext@MSK | Save
  • Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
    Journal Article

    Luckett, K. A.; Cracchiolo, J. R.; Krishnamoorthy, G. P.; Leandro-Garcia, L. J.; Nagarajah, J.; Saqcena, M.; Lester, R.; Im, S. Y.; Zhao, Z.; Lowe, S. W.; more...
    Endocrine-Related Cancer (2021)

    Fulltext@MSK | Save
  • SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies
    Journal Article

    Saqcena, M.; Leandro-Garcia, L. J.; Maag, J. L. V.; Tchekmedyian, V.; Krishnamoorthy, G. P.; Tamarapu, P. P.; Tiedje, V.; Reuter, V.; Knauf, J. A.; de Stanchina, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save